What the Study Found (In Plain English)
Published in Echocardiography (Mount Kisco, N.Y.) (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: To evaluate the effects of cardioprotective therapy (CPT) with neurohormonal inhibitors on cancer therapeutics-related cardiac dysfunction (CTRCD) in breast cancer patients, focusing on right ventricular (RV) function. Key clinical takeaway: Short-term neurohormonal cardioprotection was effective in reducing RV CTRCD.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Echocardiography (Mount Kisco, N.Y.), 2025-09-15; Phase III Randomized Trial; Rigor 88/100): Short-term neurohormonal cardioprotection was effective in reducing RV CTRCD.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.